Initial US Health Plan Disclosures On Drug Rebates And Patient Cost Sharing Postponed
Postponement of the transparency requirement established via late 2020 legislation may mean data from health plans may not be publicly available until 2024.
You may also be interested in...
The most detailed US reporting requirements regarding prescription drug costs and coverage will target medicines reimbursed under the retail pharmacy benefit.
A policy eliminating rebates in the Medicare Part D program will be delayed until Jan. 1, 2026 – and is very likely to be repealed altogether. If that staves off more draconian reforms, the biopharma industry will celebrate.
Medicare Part B payment loopholes also targeted in law, and Medicare Part D plans will need to offer real-time benefit tools for prescriber-patient decision making.